全球游离甲状腺素免疫测定标准化:专家意见综述
本文综述游离甲状腺素(FT4)免疫测定标准化的路径与特殊人群检测挑战,指出不同FT4测定结果存在差异,全球标准化可提升实验室间可比性并支持基于证据的临床决策限制定。国际临床化学与检验医学联盟甲状腺功能检测标准化委员会已开展方法比对与再校准研究,并开发了正在验证的参考测量程序,但仍需建立共同参考区间/临床决策限,且标准化将显著改变检测结果,需大规模教育计划。
要点
- 不同FT4免疫测定结果存在差异,全球标准化可改善实验室间可比性。
- 标准化将显著改变检测结果,需教育利益相关者并规划过渡程序。
- 仍需建立共同参考区间/临床决策限,并关注特殊人群的群体特异性参考区间。
核心结论
- FT4检测标准化已取得显著进展,但技术和后勤挑战依然存在。
- 实现FT4测定全球标准化需要制造商、实验室和临床医生的协作努力。
研究设计与样本
- 本文为专家意见综述,总结FT4测定标准化的路径及特殊人群检测挑战。
- 国际临床化学与检验医学联盟甲状腺功能检测标准化委员会已开展FT4免疫测定方法比对和再校准研究,并开发了正在验证的参考测量程序。
主要发现
- 不同FT4测定结果存在差异,全球标准化可改善实验室间结果可比性,并支持制定基于证据的通用临床决策限。
- FT4标准化将实质性改变检测结果,需要大规模教育计划确保利益相关者了解益处、过渡程序和潜在临床影响。
- 制造商再校准和监管机构简化审批流程有助于最小化标准化的临床影响。
关键数值与推荐
- 需进一步研究建立共同参考区间/临床决策限。
- 需开展协作努力建立群体特异性参考区间。
临床怎么用
- 临床应知晓FT4标准化将导致检测结果实质性变化,并关注教育计划与过渡程序。
- 制造商应进行测定再校准,监管机构应简化审批流程以减小标准化临床影响。
局限性
- 技术和后勤挑战仍然存在。
- 共同参考区间/临床决策限尚未建立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Results can vary between different free thyroxine (FT4) assays; global standardization would improve comparability of results between laboratories, allowing development of common clinical decision limits in evidence-based guidelines. CONTENT: We summarize the path to standardization of FT4 assays, and challenges associated with FT4 testing in special populations, including the need for collaborative efforts toward establishing population-specific reference intervals. The International Federation of Clinical Chemistry and Laboratory Medicine Committee for Standardization of Thyroid Function Tests has undertaken FT4 immunoassay method comparison and recalibration studies and developed a reference measurement procedure that is currently being validated. Further studies are needed to establish common reference intervals/clinical decision limits. Standardization of FT4 assays will change test results substantially; therefore, a major education program will be required to ensure stakeholders are aware of the benefits of FT4 standardization, planned transition procedure, and potential clinical impact of the changes. Assay recalibration by manufacturers and approval process simplification by regulatory authorities will help minimize the clinical impact of standardization. SUMMARY: Significant progress has been made toward standardization of FT4 testing, but technical and logistical challenges remain. OUTLOOK: Collaborative efforts by manufacturers, laboratories, and clinicians are required to achieve successful global standardization of the FT4 assays.
引用
- Kratzsch J, Baumann NA, Ceriotti F, et al. Global FT4 immunoassay standardization: an expert opinion review. Clin Chem Lab Med. 2020. PMID: 33554525. doi:10.1515/cclm-2020-1696
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。